Intarcia Therapeutics Stock

Intarcia Therapeutics is a biopharmaceutical company developing therapies for diseases that require long-term chronic treatment.

Sign up today and learn more about Intarcia Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Intarcia Therapeutics Stock

Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. The company's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. The company was formerly known as BioMedicines, Inc. and changed its name to Intarcia Therapeutics, Inc. in September 2004. Intarcia Therapeutics was founded in 1997 and is based in Hayward, California with an additional office in Mountain View, California.


Funding History

May 2010$14.5M
September 2010$5.0M
January 2012$83.7M
August 2012$45.8M
November 2012$160M
November 2012$50.0M
April 2014$200M
April 2015$225M
May 2016$75.0M
September 2016$215M


CFO & Vice President, Finance and Operations

James M. Ahlers

Vice President, Global Regulatory Affairs and Quality

Sunita Zalani

Vice President, General Counsel, and Chief Legal Officer

Raymond Keane

Vice President, Human Resources

James P. Brady

Head of Customer Experience & Outcomes (CXO)

Jay Smith

Executive Director, DUROS® Manufacturing

Dick Ford

Chief Operating Officer

Michael Williams

Vice President, Chief Scientific Officer

Andrew Young

Head of Discovery and Translational Medicine

Paul Feldman

Vice President, General Counsel, Corporate Secretary

Barbara McClung


prnewswire - Jun, 18 2018

Intarcia Provides Corporate Update

startupticker - Sep, 15 2017

Intarcia and Numab Reach Key Milestone

strictlyvc - Jan, 15 2017

StrictlyVC: January 3, 2017

strictlyvc - Apr, 5 2016

StrictlyVC: March 31, 2016

massdevice - Sep, 29 2015

GI Dynamics slashes workforce by 46%

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: